Chiaojung Jillian Tsai: CURB randomized phase 2 RCT of SBRT for oligoprogressive metastatic NSCLC and breast cancer

CURB randomized phase 2 RCT of SBRT for oligoprogressive metastatic NSCLC and breast cancer. SBRT improved PFS by 4 times in NSCLC, but not in oligoprogressive metastatic breast cancer in the study population. Local therapy in patients with oligoprogressive cancer might alter patterns of anatomical progression. Patients with breast cancer in either groups mostly grow new lesions while patients NSCLC in the SBRT group had fewer progressions in pre-existing lesions.Analyses of paired pre- and post-randomization blood showed that SBRT led to changes in circulating tumor DNA metrics in patients with NSCLC, but not breast cancer.

Early integration of radiotherapy in multidisciplinary management of patients with metastatic cancer is crucial for optimizing patient wellbeing and outcomes.”